Attending Biotechnology Innovation Organization's #BIO2024 Convention? Look out for Team Catalyst at tonight’s Welcome Reception. Our Advocacy, Strategy, and Business Development teams would love to connect on all things #raredisease. See you there. Check out BIO's one-on-one partnering page to connect with Catalyst's Preethi Sundaram, Stanley Iyadurai PhD MD, Jennifer Isler OCain, PhD, and more this week.
Catalyst Pharmaceuticals, Inc.
Pharmaceutical Manufacturing
Coral Gables, Florida 10,293 followers
We are focused on developing and commercializing innovative therapies for people with rare neurological diseases.
About us
About Catalyst Pharmaceuticals, Inc. Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults and children ages six to seventeen with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.
- Website
-
http://www.catalystpharma.com
External link for Catalyst Pharmaceuticals, Inc.
- Industry
- Pharmaceutical Manufacturing
- Company size
- 51-200 employees
- Headquarters
- Coral Gables, Florida
- Type
- Public Company
- Founded
- 2002
- Specialties
- Neurology, Neuromuscular, Pharmaceuticals, and Rare Disease
Locations
-
Primary
Get directions
355 Alhambra Circle
Suite 801
Coral Gables, Florida 33134, US
Employees at Catalyst Pharmaceuticals, Inc.
Updates
-
The U.S. Food and Drug Administration has approved Catalyst Pharmaceuticals, Inc.’s supplemental New Drug Application (“sNDA”) increasing the indicated maximum daily dose of FIRDAPSE® (amifampridine) for adults and pediatric patients weighing more than 45 kg from 80 mg to 100 mg for the treatment of Lambert-Eaton myasthenic syndrome (“LEMS”). The increased maximum daily dose offers healthcare providers and patients greater flexibility in treatment regimens for managing LEMS. Learn more below.
-
Our team is at the #CureDuchenne #2024FUTURES Conference, from May 23 - 26. Stop by our booth #21 to meet with our team and learn how Catalyst is working to serve the Duchenne Muscular Dystrophy (DMD) community.
-
-
In a recent interview with Investor's Business Daily, Catalyst Pharmaceuticals, Inc. CEO, Rich Daly, discussed the company's transformation during his nine years as a board member and now as CEO. He highlighted Catalyst's growth from one to three products, emphasizing the advantages of a positive work environment, and the company's continued focus on executing its strategic objectives.
Q&A: This New CEO Has Big Ideas For A Small Biotech
https://www.investors.com
-
Learn how you can save on FYCOMPA® in 3 easy steps utilizing the FYCOMPA Instant Savings Card Program (if eligible). Visit our website to get started: https://lnkd.in/g-P4XidX Please see full Prescribing Information, including BOXED WARNING: https://lnkd.in/gz9KVhM3 For the Medication Guide, visit: https://lnkd.in/gEf_PWzC
-
Happy Mother's Day! Catalyst would like to thank all mothers and providers for their unwavering efforts and daily sacrifices. This past week, we enjoyed hearing employees share about motherhood and/or their favorite memories with their moms. The shared stories showcased how mothers make an irreplaceable impact in our lives. Mothers - Thank you for all that you do today and every day!
-
-
This week is #NationalNursesWeek! Catalyst recognizes the invaluable contributions of nurses worldwide and their impact on the healthcare field and patients’ lives. We want to express our gratitude and support for the incredible work they do every day.
-
-
The Catalyst team is at American Academy of Neurology's Annual Meeting in Denver, Colorado from April 13-18! Visit booth #1553 to learn how Catalyst is committed to developing and commercializing novel medicines for patients living with rare and difficult to treat neurological diseases. #AANAM
Catalyst Pharmaceuticals, Inc.
https://catalystpharma.com
Similar pages
Browse jobs
Stock
CPRX
NASDAQ
20 minutes delay
$15.06
-0.27 (-1.761%)
- Open
- 15.13
- Low
- 14.95
- High
- 15.25
Data from Refinitiv
See more info on